IDEAYA Biosciences, Inc. (IDYA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about IDEAYA Biosciences, Inc. (IDYA)
Company Performance

Current Price

as of Oct 16, 2024

$31.00

P/E Ratio

N/A

Market Cap

$2.62B

Description

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Metrics

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerIDYA
  • Price$31+0.58%

Trading Information

  • Market Cap$2.62B
  • Float90.63%
  • Average Daily Volume (1m)1,004,048
  • Average Daily Volume (3m)691,554
  • EPS-$2.18

Company

  • Revenue$11.96M
  • Rev Growth (1yr)-100.00%
  • Net Income-$52.77M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$63.83M
  • EV$2.04B
  • EV/Revenue170.34
  • P/EN/A
  • P/S202.06
  • P/B2.53
Documents
SEC Filings
8-K (2024-10-04)
8-K (2024-09-23)
8-K (2024-08-06)
8-K (2024-07-31)
8-K (2024-07-11)
8-K (2024-07-09)
8-K (2024-07-08)
8-K (2024-06-27)
8-K (2024-06-03)
8-K (2024-05-31)
8-K (2024-05-07)
8-K (2024-03-12)
8-K (2024-02-20)
8-K (2024-01-23)
8-K (2024-01-19)
8-K (2024-01-16)
8-K (2024-01-12)
8-K (2023-12-04)
8-K (2023-11-17)
8-K (2023-11-07)
8-K (2023-10-27)
8-K (2023-10-24)
8-K (2023-10-23)
8-K (2023-09-26)
8-K (2023-08-10)
8-K (2023-07-03)
8-K (2023-06-30)
8-K (2023-06-09)
8-K (2023-06-06)
8-K (2023-05-16)
8-K (2023-05-09)
8-K (2023-04-27)
8-K (2023-04-24)
8-K (2023-03-13)
8-K (2023-03-07)
10-Q (2024-08-06)
10-Q (2024-05-07)
10-Q (2023-11-07)
10-Q (2023-08-10)
10-Q (2023-05-09)
10-K (2024-02-20)
10-K (2023-03-07)
Earnings Calls
Earnings Report 2021Q4
Earnings Report (2022-03-15)
Factset
Factset Business Description
Factset Street Account
IDEAYA Biosciences reports Q3 EPS ($0.46) vs FactSet ($0.49) [11 est, ($0.77)-(0.25)] ($28.93, 0.00) (2023-11-07T11:07:51Z)
IDEAYA Biosciences reports preliminary cash, cash equivalents and marketable securities of $511.1M as of 30-Sep-23; provides update on ATM facility with Jefferies - 8-K ($27.25, 0.00) (2023-10-24T20:31:58Z)
IDEAYA Biosciences announces proffered paper oral presentation at ESMO 2023 for Phase 2 clinical data update for darovasertib and crizotinib combination in metastatic uveal melanoma ($24.59, 0.00) (2023-10-17T10:04:40Z)
IDEAYA Biosciences announces pricing of $125.0M common stock and pre-funded warrants through JPMorgan, Goldman Sachs, Jefferies, and RBC Capital Markets ($27.25, 0.00) (2023-10-25T02:48:19Z)
IDEAYA Biosciences announces development candidate nomination of Werner Helicase Inhibitor in collaboration with GSK ($26.67, 0.00) (2023-10-09T10:02:29Z)
IDEAYA announces top-line Phase 2 results at ESMO 2023 of darovasertib and crizotinib combo in MUM, and clinical efficacy updates for Neoadjuvant UM, GNAQ/11 cutaneous melanoma, and synthetic lethality pipeline ($25.29, 0.00) (2023-10-23T10:08:37Z)